Lund, Sweden, 27 August. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, will be presenting at Pareto Securities’ 17th Annual Healthcare Conference 2026 in Stockholm, at 12:45-13:05 CEST, on Wednesday 2 September, as well as participating in a panel discussion later that day at 14:50-15:10 CEST. Read more…
Lund, Sweden, August 21, 2026. Hansa Biopharma AB (publ) (“Hansa” or the “Company”) today announces that it has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission (the “SEC”) relating to a potential initial public offering of American Depositary Shares (“ADSs”), representing the Company’s ordinary shares, in the United […]
Lund, Sweden, 8 July, 2026. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), will publish its interim report for January – June 2026 on 22 July, 2026. Interested parties may join the Company’s quarterly conference call on the same date at 14:00 CEST / 8:00 AM EDT. The event will be hosted by Renée Aguiar-Lucander, CEO, Adam Cutler, CFO, […]
SERB assumes responsibility for the commercialization of Idefirix in transplantation in the EU, UK, Switzerland, Norway, Liechtenstein, Iceland and MENA region The transaction significantly strengthens Hansa’s financial position and enables a robust US launch, subject to US approval of imlifidase Lund, Sweden, July 1, 2026. Hansa Biopharma AB (“Hansa” or “the Company”) (Nasdaq Stockholm: HNSA) and […]
Hansa Biopharma’s ConfIdeS Phase 3 abstract selected for ‘What’s Hot, What’s New’ plenary at ATC 2026 Hansa Biopharma AB, announced on Thursday that the ConfIdeS Phase 3 abstract titled “Superior 1-year eGFR Among Highly Sensitized Patients Desensitized with Imlifidase Compared to Control” had been selected to be highlighted at the closing plenary session “What’s Hot, What’s New” at the American Transplant Congress (ATC) 2026, which took place in Boston on June […]
